Italian antitrust authorities are suspecting drug giants Novartis and Roche of a cartel and have launched an investigation into the matter, according to reports. The Italian Competition Authority is looking into whether the companies colluded to keep a drug off the shelves to leave space for a more expensive drug. Reports say the companies worked to keep Avastin, a drug to tread wet age related macular degeneration, off shelves to promote Lucentis, a more expensive but approved drug. Two complaints over the matter were filed to authorities by a private healthcare association and the Italian Opthalmological Society. The two companies in question are based in Switzerland.
Featured News
FTC Moves to Block Henkel Deal for Liquid Nails Owner
Dec 14, 2025 by
CPI
US Appeals Court Hears Challenge to False Claims Act Whistleblower Powers
Dec 14, 2025 by
CPI
Federal Judge Again Throws Out Antitrust Lawsuit Against Visa
Dec 14, 2025 by
CPI
California Judge Expands Antitrust Lawsuit Against Live Nation and Ticketmaster
Dec 14, 2025 by
CPI
NY Laws Requires Disclosure of AI Actors in Ads, Limit Use of Person’s Image After Death
Dec 12, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Acqui-hiring
Dec 11, 2025 by
CPI
Anticompetitive Effects of Acquihires: Labor and Product Markets
Dec 11, 2025 by
Heski Bar-Isaac, Justin Johnson & Volker Nocke
Acquihires In the Technology Sector: Antitrust Scrutiny Through the Lens of Economics
Dec 11, 2025 by
Juliette Caminade, Rebecca Kirk Fair, Zsolt Udvari & Jeanne Vellard Smith
M&A in the AI Era: Considerations for Acquihiring
Dec 11, 2025 by
Ingrid Vandenborre, Kenneth Schwartz, Christopher Barlow, Page Griffin, Michael Cardella, Stuart Levi, Taylor Votek, Benjamin Salzer, Lisa G. Liu & Liz Kraus
Lock Them Up, or Take No Prisoners? Merger Policy and Acquiring AI Talent: Human Rights and Other Inconvenient Facts
Dec 11, 2025 by
Simon R. Pritchard